Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031720 · ClinicalTrials.gov registry record · Phase 2
Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease
A Phase 2 study of Breast Cancer and Hot Flashes, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
- 14
- Study locations
NCT00031720 is a Phase 2 study of Breast Cancer and Hot Flashes that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 112 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 14 study locations across 6 states.
The verdict
NCT00031720, a Phase 2 study of Breast Cancer and Hot Flashes, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
- 14
- Study locations
Study Summary
RATIONALE: Soy protein supplement may be effective in reducing hot flushes in postmenopausal women who are receiving tamoxifen for breast disease. PURPOSE: Randomized phase II trial to determine the effectiveness of soy protein supplement in reducing hot flushes in postmenopausal women who are receiving tamoxifen for breast disease such as ductal hyperplasia or breast cancer.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Tamoxifen
- DIETARY_SUPPLEMENT soy protein
- DIETARY_SUPPLEMENT isoflavones
Study Locations (14)
Indiana
- Elkhart General Hospital - Elkhart
- Howard Community Hospital - Kokomo
- Center for Cancer Therapy at LaPorte Hospital and Health Services - La Porte
- CCOP - Northern Indiana CR Consortium - South Bend
- Memorial Hospital of South Bend - South Bend
- Saint Joseph Regional Medical Center - South Bend
North Carolina
- Wayne Memorial Hospital, Incorporated - Goldsboro
- Kinston Medical Specialists - Kinston
- FirstHealth Moore Regional Community Hospital Comprehensive Cancer Center - Pinehurst
New Hampshire
- Kingsbury Center for Cancer Care at Cheshire Medical Center - Keene
- Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center - Lebanon
Illinois
- Center for Cancer Care at OSF Saint Anthony Medical Center - Rockford
Massachusetts
- Commonwealth Hematology-Oncology, PC - Worcester - Worcester
Michigan
- Lakeland Regional Cancer Care Center - St. Joseph - Saint Joseph
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2002-03 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00031720
The ClinicalTrials.gov registry entry for NCT00031720 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT00031720 reports 14 study locations spanning 6 distinct geographic areas - top geographies include Indiana, North Carolina, New Hampshire.
Frequently Asked Questions
What is clinical trial NCT00031720 about?
NCT00031720 is a clinical study titled "Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease". RATIONALE: Soy protein supplement may be effective in reducing hot flushes in postmenopausal women who are receiving tamoxifen for breast disease. PURPOSE: Randomized phase II trial to determine the effectiveness of soy protein supplement in reducing hot flushes in postmenopausal women who are rece...
What is the current status of trial NCT00031720?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2002-03. Estimated completion is 2013-11.
What conditions does trial NCT00031720 study?
This clinical trial studies the following conditions: Breast Cancer, Hot Flashes, Hot Flushes.
What interventions are being tested in trial NCT00031720?
The interventions under investigation include: Placebo (OTHER), Tamoxifen (DRUG), soy protein (DIETARY_SUPPLEMENT), isoflavones (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00031720?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00031720 being conducted?
This trial has 14 study locations across Illinois, Indiana, Massachusetts, Michigan, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.